187 related articles for article (PubMed ID: 37418122)
1. Comparison of the Effectiveness and Safety of Mycophenolate Mofetil and Cyclophosphamide in Lupus Nephritis: Evidence from a Real-World Study.
Zhang X; Huang H; Gao D; Zhao J; Ji L; Fan Y; Hao Y; Zhang Z
Rheumatol Ther; 2023 Oct; 10(5):1199-1213. PubMed ID: 37418122
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy and safety of mycophenolate mofetil and cyclophosphamide in the induction treatment of lupus nephritis: A systematic review and meta-analysis.
Jiang YP; Zhao XX; Chen RR; Xu ZH; Wen CP; Yu J
Medicine (Baltimore); 2020 Sep; 99(38):e22328. PubMed ID: 32957400
[TBL] [Abstract][Full Text] [Related]
3. Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial.
Sedhain A; Hada R; Agrawal RK; Bhattarai GR; Baral A
BMC Nephrol; 2018 Jul; 19(1):175. PubMed ID: 29996800
[TBL] [Abstract][Full Text] [Related]
4. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
Rathi M; Goyal A; Jaryal A; Sharma A; Gupta PK; Ramachandran R; Kumar V; Kohli HS; Sakhuja V; Jha V; Gupta KL
Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
[TBL] [Abstract][Full Text] [Related]
5. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.
Feng X; Gu F; Chen W; Liu Y; Wei H; Liu L; Yin S; Da Z; Sun L
Chin Med J (Engl); 2014; 127(21):3718-23. PubMed ID: 25382325
[TBL] [Abstract][Full Text] [Related]
6. Rituximab use as induction therapy for lupus nephritis: a systematic review.
Stolyar L; Lahita RG; Panush RS
Lupus; 2020 Jul; 29(8):892-912. PubMed ID: 32486934
[TBL] [Abstract][Full Text] [Related]
7. Induction therapy for pediatric onset class IV lupus nephritis: Mycophenolate Mofetil versus Cyclophosphamide.
Chbihi M; Eveillard LA; Riller Q; Brousse R; Berthaud R; Quartier P; Salomon R; Charbit M; Avramescu M; Biebuyck N; Dehoux L; Garcelon N; Duong-Van-Huyen JP; Bader-Meunier B; Boyer O
J Nephrol; 2023 Apr; 36(3):829-839. PubMed ID: 36208405
[TBL] [Abstract][Full Text] [Related]
8. A Comparison Of Mycophenolate Mofetil And Cyclophosphamide As Lupus Nephritis Induction Therapy.
Gul H; Mushtaq MS; Salim B; Samreen S; Nasim A; Khan M
J Ayub Med Coll Abbottabad; 2020; 32(4):454-458. PubMed ID: 33225643
[TBL] [Abstract][Full Text] [Related]
9. Eurolupus cyclophosphamide plus repeated pulses of methyl-prednisolone for the induction therapy of class III, IV and V lupus nephritis.
Ruiz-Irastorza G; Dueña-Bartolome L; Dunder S; Varona J; Gomez-Carballo C; Dominguez-Cainzos J; Rodrigo-Manjon A; Bueno L; Richez C; Duffau P; Blanco P; Lazaro E
Autoimmun Rev; 2021 Oct; 20(10):102898. PubMed ID: 34274543
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis.
Basu B; Roy B; Babu BG
Pediatr Nephrol; 2017 Jun; 32(6):1013-1021. PubMed ID: 28191596
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of cyclophosphamide and non-cyclophosphamide in the induction therapy of Malaysian lupus nephritis patients.
Rosli FZ; Shaharir SS; Abdul Gafor AH; Mohd R; Aizuddin AN; Osman S
Lupus; 2022 Aug; 31(9):1138-1146. PubMed ID: 35608373
[TBL] [Abstract][Full Text] [Related]
12. The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritis.
Koo HS; Kim YC; Lee SW; Kim DK; Oh KH; Joo KW; Kim YS; Ahn C; Han JS; Kim S; Chin HJ
Lupus; 2011 Nov; 20(13):1442-9. PubMed ID: 21951944
[TBL] [Abstract][Full Text] [Related]
13. Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil.
Joo YB; Kang YM; Kim HA; Suh CH; Kim TJ; Park YW; Lee J; Lee JH; Yoo DH; Bae SC; Lee HS; Bang SY
Int J Rheum Dis; 2018 May; 21(5):1031-1039. PubMed ID: 29611341
[TBL] [Abstract][Full Text] [Related]
14. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.
Moroni G; Raffiotta F; Trezzi B; Giglio E; Mezzina N; Del Papa N; Meroni P; Messa P; Sinico AR
Rheumatology (Oxford); 2014 Sep; 53(9):1570-7. PubMed ID: 24505125
[TBL] [Abstract][Full Text] [Related]
15. A Prospective Study on Long-Term Clinical Outcomes of Patients With Lupus Nephritis Treated With an Intensified B-Cell Depletion Protocol Without Maintenance Therapy.
Roccatello D; Sciascia S; Naretto C; Alpa M; Fenoglio R; Ferro M; Quattrocchio G; Rubini E; Rahbani E; Rossi D
Kidney Int Rep; 2021 Apr; 6(4):1081-1087. PubMed ID: 33912758
[TBL] [Abstract][Full Text] [Related]
16. Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis.
Cooper JC; Rouster-Stevens K; Wright TB; Hsu JJ; Klein-Gitelman MS; Ardoin SP; Schanberg LE; Brunner HI; Eberhard BA; Wagner-Weiner L; Mehta J; Haines K; McCurdy DK; Phillips TA; Huang Z; von Scheven E;
Pediatr Rheumatol Online J; 2018 Oct; 16(1):65. PubMed ID: 30348175
[TBL] [Abstract][Full Text] [Related]
17. Ovarian dysfunction with moderate-dose intravenous cyclophosphamide (modified NIH regimen) and mycophenolate mofetil in young adults with severe lupus: a prospective cohort study.
Sharma SK; Jain S; Bahl P; Potturi P; Rathi M; Naidu S; Sachdeva N; Dhir V; Jain S
Arthritis Res Ther; 2020 Aug; 22(1):189. PubMed ID: 32799907
[TBL] [Abstract][Full Text] [Related]
18. Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Lupus; 2015 Dec; 24(14):1520-8. PubMed ID: 26162684
[TBL] [Abstract][Full Text] [Related]
19. Comparative Efficacy and Safety of Tacrolimus, Cyclosporin A, Mycophenolate Mofetil, Cyclophosphamide, and Corticosteroids as Induction Therapy for Membranous Lupus Nephritis: A Network Meta-Analysis.
Lee YH; Song GG
Pharmacology; 2022; 107(9-10):439-445. PubMed ID: 35609529
[TBL] [Abstract][Full Text] [Related]
20. Current therapies for lupus nephritis in an ethnically heterogeneous cohort.
Rivera TL; Belmont HM; Malani S; Latorre M; Benton L; Weisstuch J; Barisoni L; Tseng CE; Izmirly PM; Buyon JP; Askanase AD
J Rheumatol; 2009 Feb; 36(2):298-305. PubMed ID: 19040310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
